Clinical Features and MicroRNA Expression Patterns Between AML Patients With DNMT3A R882 and Frameshift Mutations.

To investigate the prognostic differences between the two groups, survival analysis was performed, and the results indicated a trend toward a longer median overall survival period (OS) in the DNMT3A frameshift group (median OS 559 days) compared with that in the DNMT3A R882 group (median OS 264 days), although the differences did not reach statistical significance ( Supplementary Figure 1A ).

also in 111,027 other papers